Peptide Library

Human study PLS-00055

MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study.

Cross-sectional study · 32 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study.primary · Medicina (Kaunas, Lithuania) · 2025-02-12 · PMID 40005438 · DOI

Design and participants

Design
Cross-sectional study
Population
Chronic peritoneal dialysis patients with end-stage kidney disease, screened for sarcopenia risk
Conditions
End-stage kidney disease, Peritoneal dialysis, Sarcopenia
Planned enrollment (registry)
Not reported
Enrolled
32
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Chronic peritoneal dialysis may disturb MOTS-c balance, which may contribute to higher sarcopenia risk. Larger studies are needed to confirm this and to validate MOTS-c as a biomarker for sarcopenia risk stratification.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: MOTS-c was measured as an endogenous biomarker and never given, so no intervention effect can be assessed.
    • small or imprecise: Pilot study of only 32 peritoneal dialysis patients, as stated in the abstract.
    • abstract only: Only the abstract was available. Methods, funding and conflicts could not be checked.
    • confounding: Cross-sectional correlations between MOTS-c levels and sarcopenia risk cannot establish causation.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 40005438, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 40005438, abstract (Materials and Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 40005438, title (described as a pilot study) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 40005438, abstract (Materials and Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 40005438, abstract (Background and Objectives, sentence 3; Materials and Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).